ClinicalTrials.gg
Not yet recruitingNCT07497893FENOXUpdated Mar 27, 2026

FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)

An interventional study of Fexuprazan and NOAC therapy in Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB) and Gastrointestinal Hemorrhage (Clinically Important, Upper), sponsored by Ewha Womans University Mokdong Hospital. Not yet recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Ewha Womans University Mokdong Hospital · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Atrial Fibrillation with a site in Korea, Republic of — 61 open to participants now, 69 under way, 2 of them phase 3. Atrial Fibrillation · Korea, Republic of.

Planned enrollment
33rd of 144
1,000 · median 300
Started
2026
with 16 others
No phase
91 of 209
36 open now
Primary completion
2029-11
later than 55 of 68 live
Registered
191st of 209
by date
Lead sponsor
8 of 209
Ewha Womans University Mokdong Hospital

Among the 209 studies in Atrial Fibrillation with a site in Korea, Republic of, this one is the 33rd largest by planned enrollment of the 144 interventional ones that give a count, is one of 17 that started in 2026, is one of 91 with no phase, reaches primary completion later than 55 of the 68 other live ones, and was the 191st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

61 of the 209 studies in Atrial Fibrillation with a site in Korea, Republic of are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Atrial Fibrillation with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended for stroke prevention in non-valvular atrial fibrillation (AF). Although NOACs substantially reduce intracranial hemorrhage, upper gastrointestinal bleeding (UGIB) remains a frequent and clinically consequential complication. Proton pump inhibitors (PPIs) may reduce UGIB risk; however, concerns regarding long-term safety and pharmacodynamic variability persist. Fexuprazan, a potassium-competitive acid blocker (P-CAB), provides rapid and sustained acid suppression independent of acid activation and CYP2C19 metabolism. No randomized trial has evaluated P-CAB therapy for prevention of UGIB in anticoagulated patients.

Methods FENOX is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) superiority trial. Approximately 1,000 high-risk patients with non-valvular AF initiating NOAC therapy will be randomized 1:1 to receive fexuprazan plus NOAC therapy or NOAC therapy alone. High-risk enrichment includes advanced age, renal impairment, concomitant antiplatelet therapy, prior ulcer disease, or elevated HAS-BLED score. The primary endpoint is clinically relevant upper gastrointestinal bleeding (CR-UGIB) at 12 months, defined according to ISTH criteria. All events will be adjudicated by an independent blinded Clinical Events Committee. Primary analyses will follow the intention-to-treat principle using time-to-event methods.

Results The planned sample size provides 80% power to detect a 50% relative risk reduction in CR-UGIB, assuming a 12-month incidence of 10% in the control group. Interim safety monitoring will be conducted under independent oversight.

Conclusion FENOX is the first randomized trial designed to evaluate a P-CAB-based gastroprotective strategy for prevention of clinically relevant UGIB in high-risk patients receiving NOAC therapy. By integrating high-risk enrichment, pragmatic design, and blinded endpoint adjudication, the study aims to provide rigorous evidence to inform gastroprotective strategies in anticoagulated populations.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Upper Gastrointestinal Bleeding (UGIB)
  • Gastrointestinal Hemorrhage (Clinically Important, Upper)
  • Drug-Related Side Effects and Adverse Reactions

Keywords

  • Non-vitamin K antagonist oral anticoagulants (NOACs), potassium-competitive acid blocker (P-CAB), Upper gastrointestinal bleeding (UGIB)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Documented non-valvular atrial fibrillation
  • Receiving or initiating therapy with a non-vitamin K antagonist oral anticoagulant (NOAC) at guideline-recommended dosing
  • At least one high-risk factor for upper gastrointestinal bleeding, including:

    • Age ≥75 years
    • Chronic kidney disease ( \<60 mL/min/1.73 m²)
    • Concomitant antiplatelet therapy
    • Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) or
    • Prior peptic ulcer disease or upper gastrointestinal bleeding
    • HAS-BLED score ≥3

Exclusion criteria

Exclusion Criteria:

  • Active gastrointestinal bleeding at the time of screening
  • Requirement for mandatory long-term proton pump inhibitor (PPI) therapy that cannot be discontinued
  • Severe hepatic dysfunction
  • \<1 year
  • Known or to fexuprazan
  • Participation in another interventional clinical trial that may interfere with study outcomes
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Fexuprazan plus NOAC therapy

    Participants will receive fexuprazan 40 mg orally once daily in addition to standard-of-care non-vitamin K antagonist oral anticoagulant (NOAC) therapy at guideline-recommended dosing.

    Drug: Fexuprazan · Drug: NOAC therapy

  • Active comparator
    NOAC therapy alone

    Participants will receive standard-of-care non-vitamin K antagonist oral anticoagulant (NOAC) therapy at guideline-recommended dosing without additional gastroprotective therapy.

    Drug: NOAC therapy

Interventions

  • Fexuprazan 40 mg administered orally once daily for the duration of the study in combination with NOAC therapy.

  • DrugNOAC therapy

    Non-vitamin K antagonist oral anticoagulant therapy (e.g., apixaban, rivaroxaban, dabigatran, or edoxaban) administered according to approved labeling and guideline-recommended dosing.

06

What researchers measure

Primary outcomes

  1. Clinically relevant upper gastrointestinal bleeding (CR-UGIB)

    Clinically relevant upper gastrointestinal bleeding (CR-UGIB) defined as either: 1. ISTH-defined major upper gastrointestinal bleeding, or 2. clinically relevant non-major upper gastrointestinal bleeding requiring emergency department visit, hospitalization, endoscopic intervention, blood transfusion, or temporary interruption of NOAC therapy. All events will be adjudicated by an independent blinded Clinical Events Committee.

    Time frame: 12 months

Secondary outcomes

  1. ISTH major bleeding

    Major bleeding defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria.

    Time frame: 12 months

  2. Intracranial hemorrhage

    Occurrence of intracranial hemorrhage confirmed by neuroimaging or clinical diagnosis.

    Time frame: 12 months

  3. Ischemic stroke or systemic embolism

    Composite of ischemic stroke or systemic embolism confirmed by clinical and imaging criteria.

    Time frame: 12 months

  4. All-cause mortality

    Death from any cause during the follow-up period.

    Time frame: 12 months

  5. Net clinical outcome

    Composite of clinically relevant upper gastrointestinal bleeding, ischemic stroke/systemic embolism, intracranial hemorrhage, or all-cause death.

    Time frame: 12 months

Other outcomes

  1. Adverse events

    Any adverse events reported during the study period.

    Time frame: 12 months

  2. Serious adverse events

    Serious adverse events defined according to standard regulatory criteria.

    Time frame: 12 months

  3. Drug discontinuation due to adverse events

    Permanent discontinuation of study medication due to adverse events.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) that underlie the results reported in this study, after de-identification, will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Access criteria: Data will be made available to qualified researchers who provide a methodologically sound research proposal. Proposals should be directed to the corresponding author. Data access will be granted following review and approval by the study steering committee and execution of a data use agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Nov 2029, 35 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 35 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Mar 27, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Nov 30, 2029
CompletionEst.
Nov 30, 2032
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07497893
Lead sponsor
Ewha Womans University Mokdong Hospital
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Nov 30, 2029 (estimated)
Completion
Nov 30, 2032 (estimated)
Last update
Mar 27, 2026

Study contacts

Yeji Kim MD, PhD
Contact
lexie6169@gmail.com
+82-10-8680-9542

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion